RxDoctor Payments Data

Jeannine Laramie, MD

Family Medicine · Fresno, CANPI 1013938042

Payments from drug & device makers

$18,484in general payments, 2019–2025

Across 849 payments — averaging $21.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • AstraZeneca$2K
  • AbbVie$2K
  • Biohaven Pharmaceuticals, Inc.$1K
  • Boehringer Ingelheim$998
  • Novo Nordisk$964
  • plus $9K from 44 others

What the payments were for

  • Consulting fees$1,2006%
  • Food & beverage$17,28494%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,484 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$174,644
Medicare patients
222
Services billed
2,295

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab162$225,030
FarxigaDapagliflozin Propanediol66$102,209
EliquisApixaban43$65,988
XareltoRivaroxaban27$42,371
VascepaIcosapent Ethyl47$40,710
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$37,107
OzempicSemaglutide27$36,504
Praluent PenAlirocumab38$32,556
JardianceEmpagliflozin17$29,734
RexultiBrexpiprazole12$16,824
DapagliflozinDapagliflozin Propanediol14$16,215
MyrbetriqMirabegron17$14,313
Icosapent Ethyl22$12,048
Dexlansoprazole DrDexlansoprazole18$10,365
Ezetimibe207$5,919

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$2,202$102,20966 claims
PfizerEliquis$391$65,98843 claims
Johnson & JohnsonXarelto$529$42,37127 claims
GSKTrelegy Ellipta$439$37,10730 claims
Novo NordiskOzempic$964$36,50427 claims
Boehringer IngelheimJardiance$998$29,73417 claims
Otsuka America Pharmaceutical, Inc.Rexulti$379$16,82412 claims
Astellas Pharma US IncMyrbetriq$88$14,31317 claims
AbbVieSynthroid$2,091$3,61743 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$50$2,395201 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Fresno

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →